Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Rankning i aktier #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Aktiekurs
$43.48
Marknadsvärde
$8.97B
Förändring (1 dag)
0.37%
Förändring (1 år)
192.01%
Land
US
Handel Immunovant, Inc. (IMVT)

Kategori

Aktiekurshistorik för Immunovant, Inc. (IMVT)
Högsta slutkurs: $42.52 den 2026-08-01

Lägsta slutkurs: $9.88 den 2019-06-01
Aktiekurshistorik för Immunovant, Inc. från 2019 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) 8.62%
2025 -7.38%
2024 -34.45%
2023 163.89%
2022 99.44%
2021 -84.02%
2020 273.47%
2019 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$552.92 42.16%
US
$1.02K 50.82%
NL
$155.94 515.15%
US
$122.47 -12.71%
AU
$772.27 8.67%
CH